Brief: Avidity Biosciences Pursues Potential Accelerated Approval Path With Initiation Of Biomarker Cohort In FORTITUDE Trial For Delpacibart Braxlosiran (del-brax/AOC 1020) In People Living With Facioscapulohumeral Muscular Dystrophy
30/10/2024 13:13
Oct 30 (Reuters) - Avidity Biosciences Inc RNA.O :
* AVIDITY BIOSCIENCES PURSUES POTENTIAL ACCELERATED APPROVAL
PATH
WITH INITIATION OF BIOMARKER COHORT IN FORTITUDE™ TRIAL FOR
DELPACIBART BRAXLOSIRAN (DEL-BRAX/AOC 1020) IN PEOPLE LIVING
WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
* AVIDITY BIOSCIENCES: ENROLLMENT IN DEL-BRAX BIOMARKER
COHORT
EXPECTED TO BE COMPLETED IN 1H 2025
Source text: ID:nPn54Bk42a
Further company coverage: RNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avidity Biosciences
See all newsFactbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Brief: Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off